Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
F. Shawket,
J. Lycke,
J. Salzer,
F. Piehl,
K. Fink,
N. Lange,
J. Mellergård,
C. Malmeström,
P. Sundström,
I. Erngren,
A. al‐Grety,
E. Freyhult,
K. Kultima,
J. Burman,
A. Svenningsson Annals of Clinical and Translational Neurology
· Wiley
· 2026-11-12
· DOI: 10.1002/acn3.70395
Аннотация
Annals of Clinical and Translational Neurology, Volume 13, Issue 11, Page 2278-2288, November 2026.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange et al. Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS. // Annals of Clinical and Translational Neurology. – 2026. – DOI: 10.1002/acn3.70395. – URL: https://onlinelibrary.wiley.com/doi/10.1002/acn3.70395?af=R
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, & A. Svenningsson (2026). Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70395
F. Shawket, et al. “Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS.” Annals of Clinical and Translational Neurology, 2026. doi:10.1002/acn3.70395.
@article{Shawket2026,
title = {Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS},
author = {Shawket, F. and Lycke, J. and Salzer, J. and Piehl, F. and Fink, K. and Lange, N. and Mellergård, J. and Malmeström, C. and Sundström, P. and Erngren, I. and al‐Grety, A. and Freyhult, E. and Kultima, K. and Burman, J. and Svenningsson, A.},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
doi = {10.1002/acn3.70395},
url = {https://onlinelibrary.wiley.com/doi/10.1002/acn3.70395?af=R}
}